SEC Form 4/A · accession 0000899243-19-000973

Solid Biosciences Inc. · SLDB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — See Remarks

Period of report

Nov 15, 2018

Accepted (ET)

Jan 10, 2019 · 4:45 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001707502

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F4	Nov 15, 2018	S	13,448	$30.6778	D	133,198	D
Common Stock^F1,F3,F4	Nov 15, 2018	S	8,542	$31.0963	D	124,656	D

No Table II lines on this filing.

F1The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form.
F4Amendment corrects arithmetical error as to number of securities in Column 5 of Table I.

Chief Technology Officer and Head of Exploratory Research and Development